WO2018221479A1 - Nouvelle substance fluorescente pour analyse de fonction de transport - Google Patents

Nouvelle substance fluorescente pour analyse de fonction de transport Download PDF

Info

Publication number
WO2018221479A1
WO2018221479A1 PCT/JP2018/020440 JP2018020440W WO2018221479A1 WO 2018221479 A1 WO2018221479 A1 WO 2018221479A1 JP 2018020440 W JP2018020440 W JP 2018020440W WO 2018221479 A1 WO2018221479 A1 WO 2018221479A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
atom
acid
optionally substituted
sulfonic acid
Prior art date
Application number
PCT/JP2018/020440
Other languages
English (en)
Japanese (ja)
Inventor
山口　浩明
成康 眞野
裕 山岸
Original Assignee
五稜化薬株式会社
国立大学法人東北大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 五稜化薬株式会社, 国立大学法人東北大学 filed Critical 五稜化薬株式会社
Publication of WO2018221479A1 publication Critical patent/WO2018221479A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Definitions

  • the present invention relates to a fluorescent substrate used for functional analysis of a transporter.
  • Non-Patent Document 1 a fluorescent substrate in which chenodeoxycholic acid (CDCA) is labeled with nitrobenzooxadiazole (NBD) has been produced and reported (Non-Patent Document 1), but there are problems such as easy quenching and weak fluorescence.
  • CCDCA chenodeoxycholic acid
  • NBD nitrobenzooxadiazole
  • HTS high-throughput screening
  • an object of the present invention is to provide a fluorescent substrate that is difficult to quench and has high fluorescence intensity while maintaining the high transport ability of the transporter substrate.
  • a probe exhibiting a high S / N ratio can be created by imparting water solubility to the fluorescent substrate.
  • a fluorescent substrate in which various bile acids and Tokyo Green (TG), Tokyo Magenta (TM), or hydroxycoumarin (HC), or derivatives thereof are bonded via a linker is quenched while maintaining high transport ability. It has been found that it becomes a fluorescent substrate of a transporter that is difficult and has high fluorescence intensity.
  • the S / N ratio at the time of saturation of CDCA-NBD uptake (after 10 minutes), that is, (uptake by transporter expressing cells) / (uptake by transporter non-expressing cells (mock cells))
  • TG is 5.7
  • HC is 3.6, indicating an excellent S / N ratio, so that a fluorescent substrate that can be used in HTS has been successfully provided.
  • ALF (I) [Wherein, A is cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, ⁇ -mulicholic acid, ⁇ -mulicholic acid, ⁇ -mulicholic acid, ⁇ -mulicholic acid, hyocholic acid, hyodeoxycholic acid 7-oxo-deoxycholic acid, 7-oxo-lithocholic acid, 1-oxo-lithocholic acid, or 2-oxo-lithocholic acid, or derivatives thereof, L represents a linker, and F represents a monovalent group of a compound represented by the following formula:
  • R 1 , R 3 , R 4 , R 6 , R 9 , and R 11 are the same or different and each represents a hydrogen atom, a halogen atom, a sulfonic acid group, a salt of a sulfonic acid group, C1 ⁇ Represents a 6 alkyl group or a C1-6 alkenyl group, R 2 represents an oxygen atom or an optionally substituted nitrogen atom, R 5 represents a hydroxyl group or an optionally substituted nitrogen atom, R 7 represents an optionally substituted C1-6 alkyl group, an optionally substituted C1-6 alkoxy group, a carboxy group, a salt of a carboxy group, a sulfonic acid group, or a salt of a sulfonic acid group, n represents a natural number from 0 to 4, R 8 and R 12 are each independently a hydroxyl group, a halogen atom, an amino group, a C1-6 alkyl group, a C
  • R 10 represents a hydroxyl group or an optionally substituted nitrogen atom
  • X represents an oxygen atom or an optionally substituted silicon atom
  • the nitrogen atom which may be substituted and the substituent of the silicon atom which may be substituted are the same or different, and each may be a C1-6 alkyl group which may be substituted.
  • the substituents of the C1-6 alkyl group which may be the same or different are each a halogen atom, a carboxylic acid, a carboxylic acid salt, a sulfonic acid, or a sulfonic acid salt.
  • the group represented by A in the compound represented by the formula (I) in the present specification represents a monovalent group of a compound taken up by OATP1B1 and / or OATP1B3, specifically, cholic acid, chenodeoxycholic acid, Deoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, ⁇ -mulicholic acid, ⁇ -mulicholic acid, ⁇ -mulicholic acid, hyocholic acid, hyodeoxycholic acid, 7-oxo-deoxycholic acid, 7-oxo- It means a monovalent group of lithocholic acid, 1-oxo-lithocholic acid, and 2-oxo-lithocholic acid (hereinafter referred to as “cholic acid and the like”) or derivatives thereof.
  • a “derivative” such as cholic acid is a compound in which an arbitrary part of a group is substituted with another group or an arbitrary group is introduced while maintaining a basic steroid skeleton in cholic acid or the like. Meaning a compound that maintains the ability to be taken up by transporting polypeptide 1B1 (OATP1B1) and / or OATP1B3.
  • the linking group for cholic acid or the like or a derivative thereof to bind to L may be at any position of cholic acid or the like or a derivative thereof, but is preferably bonded at a carboxylic acid residue moiety.
  • the bonding mode can be appropriately selected according to the type of the linking group. For example, when the linking group is a carboxylic acid, the bonding mode can be bonded by an ester bond. In the present specification, the “ester bond” includes an amide bond as well as an ester bond.
  • organic anion transporting polypeptide 1B1 (OATP1B1)” is also known as SLCO1B1.
  • Organic anion transporting polypeptide 1B3 (OATP1B3)” is also known as SLCO1B3.
  • OATP1B1 and OATP1B3 are both a single carrier transporter (SLC) transporter that is specifically expressed on the hepatocyte basement membrane side and acts on the incorporation of many statins into hepatocytes. Orally administered statins are selectively taken up by hepatocytes via OATP1B1 and inhibit cholesterol biosynthesis.
  • SLC single carrier transporter
  • Whether a derivative such as cholic acid is taken up by OATP1B1 and / or OATP1B3 can be examined by the following method.
  • Cells that expressed OATP1B1, OATP1B3, and mock cells were seeded at about 2 ⁇ 10 5 cells / well in 24-well plates that were appropriately coated, and after 72 hours of growth, the cells were washed with a buffer solution. After one to several washes, buffer is added to the cells and preincubated for 10 minutes. Add a buffer containing a test cholic acid derivative conjugated with a fluorescent label, and after incubation for a certain period of time, remove the buffer and add an ice-cold buffer containing 1% bovine serum albumin (BSA). Stop the capture.
  • BSA bovine serum albumin
  • the cells are further washed several times with an ice-cold buffer solution, dried, and then the fluorescence of a measurement sample obtained by lysing the cells by adding Lysis Buffer is measured. When the fluorescence of the measurement sample is confirmed, it is determined that a derivative such as cholic acid is taken up by OATP1B1 and / or OATP1B3.
  • A is a group represented by the following formula:
  • R 13 represents a hydrogen atom or a hydroxyl group
  • R 14 and R 15 represent a hydrogen atom, a hydroxyl group or an oxygen atom
  • a solid line and a dotted line represent a single bond when R 14 or R 15 to be bonded is a hydrogen atom or a hydroxyl group, respectively, and a double bond when R 14 or R 15 to be bonded is an oxygen atom.
  • the group represented by F in the compound represented by formula (I) represents a fluorescent substance, more specifically, a monovalent group of the compound represented by the following formula:
  • R 1 , R 3 , R 4 , R 6 , R 9 , and R 11 are the same or different and each represents a hydrogen atom, a halogen atom, a sulfonic acid group, a salt of a sulfonic acid group, or C1.
  • R 2 represents an oxygen atom or an optionally substituted nitrogen atom
  • R 5 represents a hydroxyl group or an optionally substituted nitrogen atom
  • R 7 represents an optionally substituted C1-6 alkyl group, an optionally substituted C1-6 alkoxy group, a carboxy group, a salt of a carboxy group, a sulfonic acid group, or a salt of a sulfonic acid group
  • n represents a natural number from 0 to 4
  • R 8 and R 12 are each independently a hydroxyl group, a halogen atom, an amino group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group, or a C1-6 alkoxycarbonyl group.
  • R 10 represents a hydroxyl group or an optionally substituted nitrogen atom
  • X represents an oxygen atom or an optionally substituted silicon atom
  • the nitrogen atom which may be substituted and the substituent of the silicon atom which may be substituted are the same or different, and each may be a C1-6 alkyl group which may be substituted.
  • the substituents of the C1-6 alkyl group which may be the same or different are each a halogen atom, a carboxylic acid, a carboxylic acid salt, a sulfonic acid, or a sulfonic acid salt.
  • F in the compound represented by the formula (I) is preferably TokyoGreen (registered trademark) represented by the following formula that emits green fluorescence.
  • n represents a natural number of 0 to 4, and R 17 independently represents a C1-6 alkyl group, a C1-6 alkenyl group, a C1-6 alkynyl group, a C1-6 alkoxy group, a hydroxyl group, a carboxy group, Group, a sulfonic acid group, a C1-6 alkoxycarbonyl group, a halogen atom, or an amino group, and R 18 represents a C1-6 alkyl group or a C1-6 alkoxy group.
  • R 17 represents a C1-6 alkyl group, a C1-6 alkenyl group, a C1-6 alkynyl group, a C1-6 alkoxy group, a hydroxyl group, a carboxy group, a sulfonic acid group, a C1-6 alkoxycarbonyl group, a halogen atom. Or an amino group, and R 18 represents a C1-6 alkyl group or a C1-6 alkoxy group.
  • R 17 is preferably a C1-4 alkyl group or a C1-4 alkoxy group, and more preferably a methyl group or a methoxy group.
  • R 18 is preferably a C1-4 alkyl group or a C1-4 alkoxy group, and more preferably a methyl group or a methoxy group.
  • TokyoMagenta represented by the following formula is preferable.
  • n represents a natural number of 0 to 4, and each R 19 independently represents a C1-6 alkyl group, a C1-6 alkenyl group, a C1-6 alkynyl group, a C1-6 alkoxy group, a hydroxyl group, a carboxy group, It represents group, a sulfonic acid group, C1 ⁇ 6 alkoxycarbonyl group, a halogen atom, or an amino group, R 20 represents a C1 ⁇ 6 alkyl group or a C1 ⁇ 6 alkoxy group.
  • R 19 is a C1-6 alkyl group, a C1-6 alkenyl group, a C1-6 alkynyl group, a C1-6 alkoxy group, a hydroxyl group, a carboxy group, a sulfonic acid group, a C1-6 alkoxycarbonyl group, a halogen atom. Or an amino group, and R 20 represents a C1-6 alkyl group or a C1-6 alkoxy group.
  • R 19 is preferably a C1-4 alkyl group or a C1-4 alkoxy group, and more preferably a methyl group or a methoxy group.
  • R 20 is preferably a C1-4 alkyl group or a C1-4 alkoxy group, and more preferably a methyl group or a methoxy group.
  • the compound of the present invention is preferably a compound represented by the following formula (V) or formula (VI).
  • R 1 , R 3 , R 4 , R 6 , R 9 , and R 11 are the same or different and each represents a hydrogen atom, a halogen atom, a sulfonic acid group, a salt of a sulfonic acid group, C1 ⁇ Represents a 6 alkyl group or a C1-6 alkenyl group, R 2 represents an oxygen atom or an optionally substituted nitrogen atom, R 5 represents a hydroxyl group or an optionally substituted nitrogen atom, R 7 represents an optionally substituted C1-6 alkyl group, an optionally substituted C1-6 alkoxy group, a carboxy group, a salt of a carboxy group, a sulfonic acid group, or a salt of a sulfonic acid group, n represents a natural number from 0 to 4, R 8 and R 12 are each independently a hydroxyl group, a halogen atom, an amino group, a C1-6 alkyl group, a C
  • a carboxy group, a salt of a carboxy group, a sulfonic acid group, or a salt of a sulfonic acid group, R 10 represents a hydroxyl group or an optionally substituted nitrogen atom
  • X represents an oxygen atom or an optionally substituted silicon atom
  • R 13 represents a hydrogen atom or a hydroxyl group
  • R 14 and R 15 represent a hydrogen atom, a hydroxyl group or an oxygen atom
  • a solid line and a dotted line represent a single bond when R 14 or R 15 to be bonded is a hydrogen atom or a hydroxyl group, respectively, and a double bond when R 14 or R 15 to be bonded is an oxygen atom
  • the nitrogen atom which may be substituted and the substituent of the silicon atom which may be substituted are the same or different, and each may be a C1-6 alkyl group which may be substituted.
  • the substituents of the C1-6 alkyl group which may be the same or different are each a halogen atom, a carboxylic acid, a carboxylic acid salt, a sulfonic acid, or a sulfonic acid salt.
  • R 1 is preferably a hydrogen atom or a halogen atom.
  • R 2 is preferably an oxygen atom.
  • R 3 is preferably a hydrogen atom or a halogen atom.
  • R 4 is preferably a hydroxyl group or a nitrogen atom which may be substituted with a C1-6 alkyl group, and more preferably a hydroxyl group or a C1-4 alkyl group. It is a good nitrogen atom, more preferably a hydroxyl group or a nitrogen atom which may be substituted with a methyl group.
  • R 5 is preferably a hydrogen atom or a halogen atom.
  • R 6 is preferably a hydroxyl group or an optionally substituted nitrogen atom.
  • R 7 is preferably a hydroxyl group or an optionally substituted nitrogen atom.
  • X is preferably an oxygen atom or a silicon atom optionally substituted by 1 to 2 C1-6 alkyl groups, more preferably an oxygen atom or 2 C1-6 A silicon atom substituted with a 4 alkyl group, more preferably an oxygen atom, or a silicon atom substituted with two methyl groups.
  • R 9 is preferably a hydrogen atom.
  • R 10 is preferably a hydroxyl group or a di (C1-6 alkyl) amino group (preferably a dimethylamino group or a diethylamino group).
  • R 11 is preferably a hydrogen atom.
  • R 13 is preferably a hydrogen atom or a hydroxyl group.
  • R 14 and R 15 are preferably a hydrogen atom, a hydroxyl group or an oxygen atom.
  • the solid and dotted lines represent a single bond when R 14 or R 15 to be bonded is a hydrogen atom or a hydroxyl group, respectively.
  • R 14 or R 15 to be bonded is an oxygen atom, it represents a double bond.
  • the compound of the present invention is a compound represented by the formula (V),
  • R 1 represents a hydrogen atom or a halogen atom
  • R 2 represents an oxygen atom or an optionally substituted nitrogen atom
  • R 3 represents a hydrogen atom or a halogen atom
  • R 4 represents a hydroxyl group or an optionally substituted nitrogen atom
  • R 5 represents a hydrogen atom or a halogen atom
  • R 6 represents a hydroxyl group or an optionally substituted nitrogen atom
  • R 7 represents a methyl group or a methoxy group
  • X represents an oxygen atom or an optionally substituted silicon atom
  • the optionally substituted nitrogen atom and the optionally substituted silicon atom substituent are the same or different and each is a C1-6 alkyl group.
  • R 13 represents a hydrogen atom or a hydroxyl group
  • R 14 and R 15 represent a hydrogen atom, a hydroxyl group or an oxygen atom
  • a solid line and a dotted line represent a single bond when R 14 or R 15 to be bonded is a hydrogen atom or a hydroxyl group, and a double bond when R 14 or R 15 to be bonded is an oxygen atom, respectively. It is.
  • the present invention is an intermediate compound represented by the following formulas (VII) to (IX). These compounds can be used as intermediates for synthesizing the compounds of the present invention represented by the formula (I).
  • the group represented by L in the compounds represented by formulas (I), (V), (VI), (VII), (VIII), and (IX) represents a linker.
  • the linker is a group that binds cholic acid or the like or a derivative thereof to the fluorescent dye compound represented by F in formula (I).
  • the linker may be any group as long as the compound of the present invention can maintain the high transport ability of the transporter substrate represented by A and can maintain the fluorescence intensity of the fluorescent substance represented by F. There may be.
  • the linker moiety is a group that can be bonded to A and F at both ends by an ester bond, an amide bond, or a sulfonic acid amide bond, respectively.
  • L has a linear or branched C2-14 alkylene chain which may be substituted.
  • substituent when the alkylene chain of L is substituted include a hydroxyl group, amino group, halogen atom, oxo group, C1-4 alkoxy group, C1-4 alkoxycarbonyl group, C1-4 alkoxycarbonyloxy group, C1 ⁇
  • a 4-alkylaminocarboxy group, a carboxylic acid group, or a —CONH— (CH 2 ) 2 —SO 3 H group can be mentioned.
  • the number of substituents may be 1 to 4, 1 to 3, 1 to 2, or 1.
  • L is —NH— (CH 2 ) p — (CHR 21 ) q — (CH 2 ) r —NHCO— (the CO group is a group derived from R 8 or R 12 ), or —NH— (CH 2 P ⁇ (CHR 21 ) q — (CH 2 ) r —NHSO 2 — (wherein the SO 2 group is a group derived from R 8 or R 12 ) [wherein, p and r are respectively , The same or different, a natural number of 2 to 10, q is 0 or 1, and R 21 is a carboxylic acid group or a —CONH— (CH 2 ) 2 —SO 3 H group].
  • C1-6 alkyl group means a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, Examples include i-propyl group, n-butyl group, sec-butyl group, t-butyl group, isobutyl group, pentyl group, isopentyl group, 2,3-dimethylpropyl group, hexyl group, and cyclohexyl group.
  • a C1-4 alkyl group more preferably a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, a sec-butyl group, a t-butyl group, and an isobutyl group. More preferred is a C1-3 alkyl group, for example, a methyl group, an ethyl group, an n-propyl group, and an i-propyl group, and most preferred is a methyl group or an ethyl group.
  • the “C1-6 alkoxy group” means a group ((C1-6 alkyl group) -O— group) bonded to the C1-6 alkyl group via an oxygen atom.
  • the base part may be linear or branched.
  • the C1-6 alkoxy group means that the alkyl group moiety has 1 to 6 carbon atoms. Examples of the alkoxy group include a methoxy group, an ethoxy group, a 1-propyloxy group, a 2-propyloxy group, a 2-methyl-1-propyloxy group, a 2-methyl-2-propyloxy group, and 2,2-dimethyl.
  • the C1-6 alkoxy group is preferably a C1-4 alkoxy group, more preferably a C1-3 alkoxy group, still more preferably a methoxy group or an ethoxy group.
  • the “C1-6 alkoxycarbonyl group” means a group ((C1-6 alkyl group) -C ( ⁇ O) bonded to the C1-6 alkoxy group via an oxo group (> C ⁇ O). ) -Group), and the alkyl group moiety may be linear or branched.
  • the C1-6 alkoxycarbonyl group means that the alkyl group moiety has 1 to 6 carbon atoms. Examples of the alkoxy group include a methoxycarbonyl group, an ethoxycarbonyl group, a 1-propyloxycarbonyl group, a 2-propyloxycarbonyl group, a 2-methyl-1-propyloxycarbonyl group, and a 2-methyl-2-propyloxycarbonyl group.
  • 2,2-dimethyl-1-propyloxycarbonyl group 1,2-dimethyl-1-propyloxycarbonyl group, 1-butyloxycarbonyl group, 2-butyloxycarbonyl group, 2-methyl-1-butyloxycarbonyl group, 3-methyl-1-butyloxycarbonyl group, 2-methyl-2-butyloxycarbonyl group, 3-methyl-2-butyloxycarbonyl group, 1-pentyloxycarbonyl group, 2-pentyloxycarbonyl group, 3-pentyloxycarbonyl group, 2-methyl-1-pentyl Oxycarbonyl group, 3-methyl-1-penty Examples include oxycarbonyl group, 2-methyl-2-pentyloxycarbonyl group, 3-methyl-2-pentyloxycarbonyl group, 1-hexyloxycarbonyl group, 2-hexyloxycarbonyl group, and 3-hexyloxycarbonyl group.
  • the C1-6 alkoxycarbonyl group is preferably a C1-4 alkoxycarbonyl group, more preferably a C1-3 alkoxycarbonyl group, and still more preferably a methoxycarbonyl group or an ethoxycarbonyl group.
  • the “C2-6 alkenyl group” is a carbon atom formed by removing one hydrogen atom from any carbon atom of a linear or branched unsaturated hydrocarbon having one or more carbon-carbon double bonds. It means a monovalent group having 2 to 6 numbers.
  • Examples of the C2-6 alkenyl group include a vinyl group, propenyl group, isopropenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-methyl-1-propenyl group, 2-methyl-1- Propenyl group, 1-methyl-2-propenyl group, 2-methyl-2-propenyl group, 1-methylidene-1-propane group, 1-pentenyl group, 1-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl-1-butenyl group, 1-methyl-2-butenyl group, 1-methyl-3-butenyl group, 1-methylidenebutyl group, 2-methyl-1-butenyl group, 2-methyl-2-butenyl group, 2-methyl-3-butenyl group, 2-methylidenebutyl group, 3-methyl-1-butenyl group, 3-methyl-2-butenyl group, 3-methyl-3-butenyl group, 1-ethyl-1 Propenyl group,
  • the “C2-6 alkynyl group” is a carbon atom obtained by removing one hydrogen atom from any carbon atom of a linear or branched unsaturated hydrocarbon having one or more carbon-carbon triple bonds. It means a monovalent group having 2 to 6 numbers.
  • Examples of the C2-6 alkynyl group include ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, pentynyl group, hexynyl group, phenylethynyl group and the like. it can.
  • a C2-4 alkynyl group is preferable, and an ethynyl group is more preferable.
  • Halogen atom means a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, preferably a fluorine atom, a chlorine atom and a bromine atom, more preferably a fluorine atom or a chlorine atom. .
  • salt in a salt of a sulfonic acid group and a salt of a carboxy group means a salt formed by combining the compound of the present invention with an inorganic or organic base at the sulfonic acid group or carboxy group.
  • the salt examples include alkali metal and alkaline earth metal salts such as lithium, sodium, potassium, magnesium, calcium; ammonia, methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris (hydroxymethyl) aminomethane, N, N -Salts of amines such as bis (hydroxyethyl) piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglucamine, L-glucamine; or bases such as lysine, ⁇ -hydroxylysine, arginine A salt with a functional amino acid can be formed.
  • alkali metal and alkaline earth metal salts such as lithium, sodium, potassium, magnesium, calcium
  • ammonia methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris (hydroxymethyl) aminomethane, N, N -Salts of amines such as bis (hydroxyethyl) piperazine, 2-amino-2-methyl-1-propano
  • the present invention relates to a transporter function measurement kit comprising the compound.
  • Transporters include OATP1B1 and / or OATP1B3.
  • the kit of the present invention may comprise a container for storing the compound, an instruction manual, and a package for storing the components of the kit such as a paper box or a plastic case.
  • the fluorescent substrate of the present invention can provide a fluorescent substrate for a transporter that can be put to practical use because it maintains high transporter transportability and is not easily quenched and has high fluorescence intensity.
  • CDCA-Lys-TG 0.025 ⁇ M
  • CDCA-Lys-HC 0.1 ⁇ M
  • CDCA-Lys-DCTM 0.01 ⁇ M
  • CDCA-Lys-Et 2 AC 0. Set to 1 ⁇ M (D).
  • each graph represents the amount of uptake per 1 mg of protein (uptake) (pmol / mg protein), and the horizontal axis represents the elapsed time (minutes).
  • a white circle represents a cell into which an empty vector has been introduced (control)
  • a black triangle represents a cell into which OATP1B1 has been introduced
  • a black square represents a cell into which OATP1B3 has been introduced.
  • 2 is a graph showing the concentration dependency of CDCA-Lys-TG uptake in OATP1B1-expressing HEK293 cells.
  • the vertical axis of the small graph represents the uptake amount after 30 seconds per mg of protein (pmol / mg protein / 30 sec), and the horizontal axis represents the uptake amount after 30 seconds per mg of protein divided by the concentration of the fluorescent substrate. Value (ml / mg protein / 30 sec) (same in FIGS. 2B to 3D and FIGS. 3A to 3D).
  • 2 is a graph showing the concentration dependence of CDCA-Lys-HC uptake in OATP1B1 and OATP1B3 expressing HEK293 cells. It is a graph showing the concentration dependence of CDCA-Lys-DCTM uptake in OATP1B1-expressing HEK293 cells. It is a graph showing the concentration dependence of uptake of CDCA-Lys-Et 2 AC in OATP1B1-expressing HEK293 cells. 2 is a graph showing the concentration dependency of CDCA-Lys-TG uptake in OATP1B3-expressing HEK293 cells. 2 is a graph showing the concentration dependency of CDCA-Lys-HC uptake in OATP1B3-expressing HEK293 cells.
  • each graph represents the amount of uptake per mg of protein (uptake) (pmol / mg protein), the horizontal axis represents the elapsed time (minutes), and the white circle represents the cells into which the empty vector was introduced (control).
  • the black triangle represents a cell into which OATP1B1 has been introduced, and the black square represents a cell into which OATP1B3 has been introduced (the same applies to FIGS. 5B and C and FIG. 6).
  • the compound of the present invention can be obtained by binding cholic acid or the like or a derivative thereof and a fluorescent dye F through a linker while referring to the Examples of the present application.
  • it can be obtained by attaching a linker to cholic acid or the like or a derivative thereof, and then attaching a fluorescent dye to the remaining end of the linker.
  • it can be obtained by binding a linker to a fluorescent dye and then binding cholic acid or the like or a derivative thereof to the remaining end of the linker.
  • Cholic acid or the like or derivatives thereof can be synthesized by methods described in the literature, or can be obtained as commercially available reagents. Moreover, the coupling
  • Fluorescent dye F is disclosed in WO 2012/099218 and Yasuteru Urano et al. am. Chem. soc (2005) 127: 4888-4894 and the like.
  • the binding between the fluorescent dye and the linker is carried out, for example, by introducing an N-succinimide group into the carboxy group of the fluorescent dye using N-hydroxysuccinimide (NHS), and then this N-succinimide fluorescent dye and cholic acid or the like It can be obtained by binding a derivative-bound linker.
  • the present invention is a method for determining whether a test substance is transported by OATP1B1 and / or OATP1B3, the method comprising the following steps: Contacting the test substance and the compound of the present invention with an OATP1B1 and / or OATP1B3-expressing cell culture, Removing the test substance and the compound of the present invention that have not been taken up into the cells, A step of measuring the fluorescence intensity of the compound of the present invention incorporated into the cell, and the obtained fluorescence intensity is contacted with the OATP1B1 and / or OATP1B3 expressing cell in the absence of the test substance in the same manner; And a step of determining that the test substance is transported by OATP1B1 and / or OATP1B3 when it is smaller than the fluor
  • the step of bringing the test substance and the compound of the present invention into contact with an OATP1B1 and / or OATP1B3 expressing cell culture comprises culturing OATP1B1 and / or OATP1B3 expressing cells on a dish, This can be done by replacing with a buffer containing the compound.
  • the test substance and the compound of the present invention that have not been taken up into the cells can be removed, for example, by removing the buffer solution and then adding a buffer solution containing BSA.
  • the fluorescence intensity of the compound of the present invention incorporated into the cells is measured by measuring the fluorescence of the cell lysate obtained by drying the cells and then lysing the cells by adding a cell lysis buffer. be able to.
  • the fluorescence can be measured with a commercially available measuring instrument by selecting an excitation wavelength and a fluorescence wavelength suitable for the fluorescent substance that binds to the compound of the present invention used (see Table 1).
  • the determination of whether or not the test substance is transported by OATP1B1 and / or OATP1B3 is based on the control in which only the compound of the present invention is contacted with the OATP1B1 and / or OATP1B3 expressing cell culture without contacting the test substance. This is done by comparing with the obtained fluorescence intensity. If the fluorescence intensity is comparable to the control, it can be determined that it is not transported by OATP1B1 and / or OATP1B3, and if the fluorescence intensity is lower than the control, it can be determined that it is transported by OATP1B1 and / or OATP1B3.
  • the fluorescence intensity of the control is such that only the compound of the present invention is brought into contact with OATP1B1 and / or OATP1B3 expressing cell culture, the compound of the present invention that has not been taken up into the cells is removed, and It is obtained by measuring the fluorescence intensity of the compound.
  • the screening method of the present invention can be performed by quenching using a quencher without removing the test substance and the compound of the present invention.
  • the present invention is a method for determining whether a test substance is transported by OATP1B1 and / or OATP1B3, the method comprising the following steps: Contacting the test substance and the compound of the present invention with an OATP1B1 and / or OATP1B3-expressing cell culture, Adding a quencher to the cell culture to quench the compounds of the invention that have not been taken up into the cells; A step of measuring the fluorescence intensity of the compound of the present invention incorporated into the cell, and the obtained fluorescence intensity is contacted with the OATP1B1 and / or OATP1B3 expressing cell in the absence of the test substance in the same manner; And a step of determining that the test substance is transported by OATP1B1 and / or OATP1B3 when it is smaller than the fluorescence intensity of the compound of the present invention
  • the compound used as a quencher is not particularly limited as long as it can quench the compound of the present invention and is not taken up by cells, and can be selected according to the fluorescent dye to be used.
  • the fluorescent dye for example, brilliant black (4-acetylamino-5-hydroxy-6- [7-sodiosulfo-4- [4- (sodiosulfo) phenylazo] -1-naphthylazo] naphthalene-1,7-disulfonic acid disodium as a quencher CAS number 2519-30-4) can be used.
  • the fluorescence intensity per unit weight of the protein can also be used as the fluorescence intensity. Therefore, the present invention is a method for determining whether or not a test substance is transported by OATP1B1 and / or OATP1B3, the method comprising the following steps: Contacting the test substance and the compound of the present invention with an OATP1B1 and / or OATP1B3-expressing cell culture, A step of removing the test substance and the compound of the present invention that has not been taken up into the cells, or a quencher is added to the cell culture to quench the compound of the present invention that has not been taken up into the cells.
  • Step to make Measuring the fluorescence intensity of the compound of the present invention incorporated into the cells.
  • the step of measuring the protein concentration in the cell lysate, and the obtained (fluorescence intensity / protein concentration) are contacted with OATP1B1 and / or OATP1B3 expressing cells in the same manner in the absence of the test substance. It is related to the step of determining that the test substance is transported by OATP1B1 and / or OATP1B3 when it is small compared with (fluorescence intensity / protein concentration) of the compound of the present invention incorporated in the inside.
  • Protein concentration can be measured by Bradfold or the like. For example, it can be performed by measuring the fluorescence of the cell lysate obtained by drying the cells into which the fluorescent substrate has been incorporated and then adding NaOH or the like to lyse the cells. The protein concentration can be determined by creating a calibration curve using BSA as a standard substance and the absorbance obtained in the sample as the concentration on the calibration curve.
  • Example 1 Synthesis of Compounds 1 to 10 In order to evaluate transporter transport ability, the following compounds 1-10 were synthesized.
  • TM-COOH 43.0 mg, 0.111 mmol
  • NHS 25.5 mg, 0.222 mmol
  • DIC 43.0 microliters, 0.278 mmol
  • Example 2 Evaluation of uptake by OATP1B1 and OATP1B3 expressing cells (1) Culturing of OATP1B1 and OATP1B3 expressing HEK293 cells OATP1B1 and OATP1B3 stably expressing HEK293 cells have already been established (Yamaguchi et al., 200, Cancer, et al. 163-169; Yamaguchi et al., Biol. Pharm. Bull. 2011; 34; 389-395). As a control, HEK293 cells (mock cells) into which an empty vector was introduced were used.
  • OATP1B1 / HEK293, OATP1B3 / HEK293 cells and mock cells were used in a medium containing 10% FBS and G-418 (0.5 mg / mL) in Dulbecco's modified Eagle's medium in a 5% CO 2 environment. Cultured at 37 ° C. These cells were maintained by subculture using a plastic dish every 3 or 4 days.
  • Fluorescent substrate As fluorescent substrates, CDCA-Lys-TG, CDCA-Lys-HC, CDCA-Lys-DCTM, CDCA-Lys-Et 2 AC, CDCA-Lys-TM, CDCA-Lys-DFTG, CDCA-Lys -SiR, CDCA-C2-DCTM, CDCA-C5-DCTM, CDCA-Lys-DCTM, CA-Tauro-nor-HC, and CA-Tauro-nor-TG were used. Table 1 shows the measurement excitation wavelength, (Excitation wavelength) (nm), and fluorescence wavelength (nm) of each fluorescent substrate.
  • OATP1B1 / HEK293, OATP1B3 / HEK293 cells and mock cells were seeded at about 200,000 cells / well on poly-L-lysine coated 24-well plates and grown for 72 hours. . The medium was changed 24 hours before the uptake experiment.
  • the cells were mixed with Krebs-Henseleit (KH) buffer (118 mM NaCl, 23.8 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM N- (2-hydroxyethyl) piperazine- After washing once with N′-2-ethanesulfonic acid (HEPES), 5.0 mM D-glucose, and 1.53 mM CaCl 2 , pH 7.4), KH buffer was added to the cells, and preincubation was performed for 10 minutes.
  • KH buffer 118 mM NaCl, 23.8 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM N- (2-hydroxyethyl) piperazine-
  • HEPES N′-2-ethanesulfonic acid
  • Incorporation was started by replacing with KH buffer containing each fluorescently labeled compound (or each fluorescently labeled compound and inhibitor). The uptake reaction was stopped by removing the incubation buffer after the specified time of incubation and adding ice-cooled KH buffer containing 1% of bovine serum albumin (BSA). The cells were further washed twice with ice-cooled KH buffer, dried, and lysed with Lysis Buffer added to obtain a fluorescence measurement sample. A microplate reader Infinite 200 PRO (Tecan Japan, Kanagawa, Japan) was used for fluorescence measurement. Wash with ice-cooled KH buffer twice, dry, add 0.5N NaOH and dissolve it as a protein quantification sample, and determine protein concentration by Bradford method using bovine serum albumin (BSA) as standard did.
  • BSA bovine serum albumin
  • the protein quantification sample performed protein quantification by Bradford method. To each well of 96 well plate, 5 ⁇ L of a protein quantification sample and 200 ⁇ L of 5-fold diluted Bio-Rad Protein Assay Reagent Concentrate (Bio-Rad Laboratories, Hercules, CA, USA) were added, and after 5 minutes, the absorbance at an absorption wavelength of 595 nm was measured. It was measured. A calibration curve was prepared using BSA as the standard protein.
  • the transporter-specific uptake was calculated by subtracting the transporter non-specific uptake by mock cells (Vec / HEK cells) from the uptake of OATP1B1 / HEK cells and OATP1B3 / HEK cells. Michaelis-Menten wave and Eadie Hofste Plot were created using data analysis software Kaleida Graph (HuLinks Inc, Tokyo, Japan). In the inhibition test, the amount of transporter-specific uptake in the absence of an inhibitor was taken as 100%, and Uptake% of Control was calculated. The test of significant difference between the Control group and the inhibitor (or PAH) group was performed by Dannett test using statistical analysis software JMP Pro 12 (SAS Institute Inc., North Carolina, USA) (* p ⁇ 0.05). ).
  • Inhibition constants of each inhibitor in transport through OATP1B1 are shown in Table 3, and inhibition constants of each inhibitor in transport through OATP1B3 are shown in Table 4 (in the table, [1] Izumi et al., Drug Metab Dispos. 2013 Oct; 41 (10): 1859-66; [2] Matsushima et al., Drug Metab Dispos. 2008 Apr; 36 (4): 663-9; [3] Tahara et al., Drug Metas 34: 74 -747, 2006).
  • the inhibition constant in the transport via OATP1B1 and OATP1B3 shows that the value of most inhibitors is 0.1 when compared with the case where a fluorescent substrate is used and the case where Estradiol-17 ⁇ -glucuronide or Fexofenadine which are known substrates are used. Correlation within -10 times was shown. This suggests that CDCA-Lys-TG, CDCA-Lys-HC, CDCA-Lys-DCTM, and CDCA-Lys-Et 2 AC exhibit inhibitory sensitivities comparable to known substrates of OATP1B1 and OATP1B3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Le but de la présente invention est de fournir un substrat fluorescent pour un transporteur, le substrat fluorescent conservant une performance de transport élevée tout en étant peu susceptible d'être éteint et présentant une forte intensité de fluorescence. La présente invention concerne un composé représenté par la formule (I). Formule (I) : A-L-F [dans la formule : A représente l'acide cholique, l'acide chénodésoxycholique, l'acide désoxycholique, l'acide lithocholique, l'acide ursocholique, l'acide ursodésoxycholique, l'acide α-muricholique, l'acide β-muricholique, l'acide ω-muricholique, l'acide hyocholique, l'acide hyodésoxycholique, l'acide 7-oxo-désoxycholique, l'acide 7-oxo-lithocholique, l'acide 1-oxo-lithocholique, l'acide 2-oxo-lithocholique ou un dérivé de ceux-ci ; L représente un lieur ; et F représente le vert de Tokyo (TG), le magenta de Tokyo (TM), l'hydroxycoumarine (HC), ou un dérivé de ceux-ci.]
PCT/JP2018/020440 2017-05-29 2018-05-29 Nouvelle substance fluorescente pour analyse de fonction de transport WO2018221479A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017105444A JP2018199648A (ja) 2017-05-29 2017-05-29 新規トランスポーター機能解析用蛍光物質
JP2017-105444 2017-05-29

Publications (1)

Publication Number Publication Date
WO2018221479A1 true WO2018221479A1 (fr) 2018-12-06

Family

ID=64455071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/020440 WO2018221479A1 (fr) 2017-05-29 2018-05-29 Nouvelle substance fluorescente pour analyse de fonction de transport

Country Status (2)

Country Link
JP (1) JP2018199648A (fr)
WO (1) WO2018221479A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072891A (ja) * 1993-05-08 1995-01-06 Hoechst Ag 単量体胆汁酸誘導体、その調製方法および医薬としてのこれらの化合物の使用
WO2002012267A1 (fr) * 2000-08-10 2002-02-14 Norgine Europe Bv Procede de production de derives d'acide biliaire a fluoresceine
GB2459976A (en) * 2008-05-15 2009-11-18 Norgine Bv Determining functional activity of MRP2 and/or MRP3 efflux pathway
WO2014029756A1 (fr) * 2012-08-20 2014-02-27 Novassay Sa Dosage de la cholyl-l-lysyl-fluorescéine
CN105541955A (zh) * 2015-12-16 2016-05-04 中国药科大学 23-羟基白桦酸荧光探针、制备及其在细胞定位与摄取中的用途
WO2017035501A1 (fr) * 2015-08-27 2017-03-02 Academia Sinica Inhibiteurs de sialyltransférase et utilisations de ceux-ci

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072891A (ja) * 1993-05-08 1995-01-06 Hoechst Ag 単量体胆汁酸誘導体、その調製方法および医薬としてのこれらの化合物の使用
WO2002012267A1 (fr) * 2000-08-10 2002-02-14 Norgine Europe Bv Procede de production de derives d'acide biliaire a fluoresceine
GB2459976A (en) * 2008-05-15 2009-11-18 Norgine Bv Determining functional activity of MRP2 and/or MRP3 efflux pathway
WO2014029756A1 (fr) * 2012-08-20 2014-02-27 Novassay Sa Dosage de la cholyl-l-lysyl-fluorescéine
WO2017035501A1 (fr) * 2015-08-27 2017-03-02 Academia Sinica Inhibiteurs de sialyltransférase et utilisations de ceux-ci
CN105541955A (zh) * 2015-12-16 2016-05-04 中国药科大学 23-羟基白桦酸荧光探针、制备及其在细胞定位与摄取中的用途

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BARBER, J. A. ET AL.: "Quantification of drug- induced inhibition of canalicular cholyl-1-lysyl- fluorescein excretion from hepatocytes by high content cell imaging", TOXICOLOGICAL SCIENCES, vol. 148, no. 1, 2015, pages 48 - 59, XP055570388, ISSN: 1096-0929 *
BAXTER, D. J. ET AL.: "Biliary lipid output by isolated perfused rat livers in response to cholyl- lysylfluorescein", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1256, no. 3, 1995, pages 374 - 380, XP000615216, ISSN: 0925-4439 *
CANTORE, M. ET AL.: "The Src Family Kinase Fyn Mediates Hyperosmolarity-induced Mrp2 and Bsep Retrieval from Canalicular Membrane", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 52, 2011, pages 45014 - 45029, XP055570395, ISSN: 0021-9258 *
DATABASE Registry CAS; 19 June 2018 (2018-06-19), Database accession no. 787542-95-4 *
DE MEY, C. ET AL.: "Effects of renal insufficiency on the elimination of fluorescein lisicol (NRL972), an investigational marker of hepatic transporter function", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 53, no. 7, 2015, pages 523 - 530, ISSN: 0946-1965 *
DE WAART, D. R . ET AL.: "Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 334, no. 1, 2010, pages 78 - 86, XP055090728, ISSN: 0022-3565 *
GUO, H. ET AL.: "Competitive affinity-based proteome profiling and imaging to reveal potential cellular targets of betulinic acid", CHEMICAL COMMUNICATIONS, vol. 53, no. 69, 7 August 2017 (2017-08-07), Cambridge, United Kingdom, pages 9620 - 9623, XP055570447, ISSN: 1359-7345 *
HOLZINGER, F. ET AL.: "Transport of fluorescent bile acids by the isolated perfused rat liver: kinetics, sequestration, and mobilization", HEPATOLOGY ( PHILADELPHIA), vol. 28, no. 2, 1998, pages 510 - 520, XP055570400, ISSN: 0270-9139 *
MAITRA, U. ET AL.: "Bile acid derived PET-based cation sensors: molecular structure dependence of their sensitivity", CHEMISTRY - AN ASIAN JOURNAL, vol. 4, no. 6, 2009, pages 989 - 997, XP055570434, ISSN: 1861-4728 *
MILKIEWICZ, P. ET AL.: "Visualization of the transport of primary and secondary bile acids across liver tissue in rats: In vivo study with fluorescent bile acids", JOURNAL OF HEPATOLOGY, vol. 34, no. 1, 2001, pages 4 - 10, XP027303116, ISSN: 0168-8278 *
MILLS, C. 0. ET AL.: "Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: A study in isolated hepatocyte couplets and TR - rats", JOURNAL OF HEPATOLOGY, vol. 31, no. 4, October 1999 (1999-10-01), pages 678 - 684, XP085003936, ISSN: 0168-8278 *
SUN, J. ET AL.: "Biological deoxycholic acid- coumarin conjugates: photo-switchable structures and self-assembly morphology", TETRAHEDRON LETTERS, vol. 57, no. 19, 2016, pages 2125 - 2128, XP029512949, ISSN: 0040-4039 *

Also Published As

Publication number Publication date
JP2018199648A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
Peng et al. Fluorescent probes based on nucleophilic substitution–cyclization for hydrogen sulfide detection and bioimaging
JP5228190B2 (ja) パーオキシナイトライト蛍光プローブ
US10006913B2 (en) Fluorescent-HAP: a diagnostic stain for HBV cores in cells
Cardoso et al. Chain length effect on the binding of amphiphiles to serum albumin and to POPC bilayers
US10113968B2 (en) Specific detection and quantification of cardiolipin and isolated mitochondria by positively charged AIE fluorogens and method of manufacturing thereof
AU2019319901B2 (en) Silicon-substituted rhodamine dyes and dye conjugates
US20220144860A1 (en) Fluorescent gtp analogues and use
Zhou et al. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors
WO2018221479A1 (fr) Nouvelle substance fluorescente pour analyse de fonction de transport
Polshakov et al. NMR screening and studies of target–ligand interactions
AU2002334874B2 (en) Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
JP5561692B2 (ja) 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法
CN107033100B (zh) 一种苯并噻唑衍生物、制备方法及其医药用途
Aoki et al. Design and synthesis of a photocleavable biotin-linker for the photoisolation of ligand–receptor complexes based on the photolysis of 8-quinolinyl sulfonates in aqueous solution
Фалетров et al. Interaction of nitrobenzoxadiazole derivatives of piperazine and aniline with bovine serum albumine in silico and in vitro
Goretta et al. Effects of chemical modification of sphingomyelin ammonium group on formation of liquid-ordered phase
JP6449632B2 (ja) フルオレセイン誘導体またはその塩、グルタチオン−ｓ−トランスフェラーゼ測定用蛍光プローブ、およびこれを用いたグルタチオン−ｓ−トランスフェラーゼ活性の測定方法
EP2396418A1 (fr) Procédés pour la détection de chaînes acyles grasses
JP2007055956A (ja) 蛍光標識試薬及び疎水場検出試薬としての新規キノリン化合物
JP7058081B2 (ja) サイクリン依存性キナーゼ基質
CN102621299B (zh) 他克莫司检测方法
WO2016114722A1 (fr) Sonde sélective vis-à-vis des cellules alpha pour imagerie à deux photons ex vivo de cellules alpha dans des îlots pancréatiques intacts
CN103012193B (zh) 隐色孔雀石绿半抗原、人工抗原及制备方法
EP2907877A1 (fr) Réactif d'imagerie destiné à l'acétylation au sein d'une cellule
US20220308043A1 (en) Fluorescent probes for identification and quantification of hepatic transporters in vitro and in vivo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18810199

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18810199

Country of ref document: EP

Kind code of ref document: A1